Literature DB >> 22896337

Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells.

Masaki Shiota1, Anousheh Zardan, Ario Takeuchi, Masafumi Kumano, Eliana Beraldi, Seiji Naito, Amina Zoubeidi, Martin E Gleave.   

Abstract

TGF-β promotes epithelial-mesenchymal transition (EMT) and induces clusterin (CLU) expression, linking these genes to cancer metastasis. CLU is a pleiotropic molecular chaperone that confers survival and proliferative advantage to cancer cells. However, the molecular mechanisms by which TGF-β regulates CLU expression and CLU affects metastasis remain unknown. In this study, we report that the transcription factor Twist1 mediates TGF-β-induced CLU expression. By binding to E-boxes in the distal promoter region of CLU gene, Twist1 regulated basal and TGF-β-induced CLU transcription. In addition, CLU reduction reduced TGF-β induction of the mesenchymal markers, N-cadherin and fibronectin, thereby inhibiting the migratory and invasive properties induced by TGF-β. Targeted inhibition of CLU also suppressed metastasis in an in vivo model. Taken together, our findings indicate that CLU is an important mediator of TGF-β-induced EMT, and suggest that CLU suppression may represent a promising therapeutic option for suppressing prostate cancer metastatic progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896337     DOI: 10.1158/0008-5472.CAN-12-0254

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

1.  Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.

Authors:  Bing Song; Su-Hong Park; Jonathan C Zhao; Ka-Wing Fong; Shangze Li; Yongik Lee; Yeqing A Yang; Subhasree Sridhar; Xiaodong Lu; Sarki A Abdulkadir; Robert L Vessella; Colm Morrissey; Timothy M Kuzel; William Catalona; Ximing Yang; Jindan Yu
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

2.  Plasticity within the niche ensures the maintenance of a Sox2+ stem cell population in the mouse incisor.

Authors:  Maria Sanz-Navarro; Kerstin Seidel; Zhao Sun; Ludivine Bertonnier-Brouty; Brad A Amendt; Ophir D Klein; Frederic Michon
Journal:  Development       Date:  2018-01-08       Impact factor: 6.868

3.  LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a.

Authors:  Jiaqian Liang; Yirong Li; Garrett Daniels; Karen Sfanos; Angelo De Marzo; Jianjun Wei; Xin Li; Wenqiang Chen; Jinhua Wang; Xuelin Zhong; Jonathan Melamed; Jun Zhao; Peng Lee
Journal:  Mol Cancer Res       Date:  2015-01-13       Impact factor: 5.852

Review 4.  The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.

Authors:  Rhonda L Bitting; Daneen Schaeffer; Jason A Somarelli; Mariano A Garcia-Blanco; Andrew J Armstrong
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 5.  Novel therapies for the treatment of advanced prostate cancer.

Authors:  J M Clarke; A J Armstrong
Journal:  Curr Treat Options Oncol       Date:  2013-03

6.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.

Authors:  Tao Yin; Guoping Wang; Sisi He; Guobo Shen; Chao Su; Yan Zhang; Xiawei Wei; Tinghong Ye; Ling Li; Shengyong Yang; Dan Li; Fuchun Guo; Zeming Mo; Yang Wan; Ping Ai; Xiaojuan Zhou; Yantong Liu; Yongsheng Wang; Yuquan Wei
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

Review 7.  SMAD7: a timer of tumor progression targeting TGF-β signaling.

Authors:  Lingyu Luo; Nianshuang Li; Nonghua Lv; Deqiang Huang
Journal:  Tumour Biol       Date:  2014-06-17

8.  Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.

Authors:  Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

9.  Serum differential protein identification of Xinjiang Kazakh esophageal cancer patients based on the two-dimensional liquid-phase chromatography and LTQ MS.

Authors:  Cui Li; Guo Xia; Zhang Jianqing; Yang Mei; Bai Ge; Zhang Li
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

10.  RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Authors:  Robert C Smallridge; Ana-Maria Chindris; Yan W Asmann; John D Casler; Daniel J Serie; Honey V Reddi; Kendall W Cradic; Michael Rivera; Stefan K Grebe; Brian M Necela; Norman L Eberhardt; Jennifer M Carr; Bryan McIver; John A Copland; E Aubrey Thompson
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.